By Staff writer
Studies to be carried out on two types of vaccinations involving more than 15,000 volunteers
Health authorities in the UAE have announced a second phase III clinical trial of a potential Covid-19 vaccine, following approval from the Ethics Committee Scientific Research in Abu Dhabi.
Dr. Abdul Rahman bin Mohammad bin Nasser Al Owais, Minister of Health and Prevention (MoHAP) revealed that research studies will now be carried out on two types of vaccinations involving more than 15,000 volunteers.
In most cases, the first phase of a clinical trial process examines the safety of a potential vaccine, while the second phase evaluates immunogenicity and evaluates the immunisation process in a limited number of people.
The third phase of a trial process examines the effectiveness of a vaccine on a larger population sample. If the vaccine is effective and deemed to be safe, it can enter into a large-scale manufacturing phase.
Last month it was revealed that a partnership between Chinese pharmaceutical giant Sinopharm China National Biotec Group (CNBG) and Group 42 (G42), an Abu Dhabi-based AI and cloud computing firm, had entered third phase testing for a vaccine, with the hope that it could enter the market by the end of 2020 or early 2021.
At the daily press briefing on Monday it was announced that the UAE has conducted more than four million Covid-19 tests since the outbreak of the global pandemic.
Dr. Amna Al-Dahhak Al-Shamsi, the official spokesman for the UAE Government, said that 34,478 tests had been carried out in the previous 24 hours, with 344 new cases of Covid-19 discovered, taking the total number of cases across the country to 55,198.
A further fatality was announced, bringing the death toll in the UAE at the hands of Covid-19 up to 334.
However, Dr Al-Shamsi revealed that 373 more patients had recovered from the virus, with 45,513 recoveries in total.